内容标题14

  • <tr id='0zcvKJ'><strong id='0zcvKJ'></strong><small id='0zcvKJ'></small><button id='0zcvKJ'></button><li id='0zcvKJ'><noscript id='0zcvKJ'><big id='0zcvKJ'></big><dt id='0zcvKJ'></dt></noscript></li></tr><ol id='0zcvKJ'><option id='0zcvKJ'><table id='0zcvKJ'><blockquote id='0zcvKJ'><tbody id='0zcvKJ'></tbody></blockquote></table></option></ol><u id='0zcvKJ'></u><kbd id='0zcvKJ'><kbd id='0zcvKJ'></kbd></kbd>

    <code id='0zcvKJ'><strong id='0zcvKJ'></strong></code>

    <fieldset id='0zcvKJ'></fieldset>
          <span id='0zcvKJ'></span>

              <ins id='0zcvKJ'></ins>
              <acronym id='0zcvKJ'><em id='0zcvKJ'></em><td id='0zcvKJ'><div id='0zcvKJ'></div></td></acronym><address id='0zcvKJ'><big id='0zcvKJ'><big id='0zcvKJ'></big><legend id='0zcvKJ'></legend></big></address>

              <i id='0zcvKJ'><div id='0zcvKJ'><ins id='0zcvKJ'></ins></div></i>
              <i id='0zcvKJ'></i>
            1. <dl id='0zcvKJ'></dl>
              1. <blockquote id='0zcvKJ'><q id='0zcvKJ'><noscript id='0zcvKJ'></noscript><dt id='0zcvKJ'></dt></q></blockquote><noframes id='0zcvKJ'><i id='0zcvKJ'></i>

                Fully Integrated Platform

                Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical needs in three therapeutic areas: viral, cancer and fatty liver diseases. Led by a management team with deep expertise and a proven track record, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

                Antibody-based Immunotherapy

                ASC22,PD-L1 antibody for HBV, first-in-class, subcutaneous, room temperature stable,phase 2 ready.

                First/Best-in-Class Small Molecules

                ASC40, first-in-class FASN inhibitor for NASH, phase 2 ready. ASC09, best-in-class HIV protease inhibitor with unprecedented genetic barrier, phase 2.

                siRNA

                ASC06, first systematically delivered, dual-targeting siRNA for liver cancer, phase 1.

                Imagine what you could do at Ascletis

                Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.

                Our mission is to become a world-class biotechnology company addressing unmet medical needs in three therapeutic areas: anti-viral, cancer and fatty liver disease, for the patients in China and worldwide. Our highly talented team of researchers and professionals who passionately share in this common mission.

                We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to hr@ascletis.com. We will look to match any current and upcoming openings to your area of expertise.